WO2001034169A1 - Utilisation d'un extrait de plantago lanceolata - Google Patents

Utilisation d'un extrait de plantago lanceolata Download PDF

Info

Publication number
WO2001034169A1
WO2001034169A1 PCT/DE2000/003956 DE0003956W WO0134169A1 WO 2001034169 A1 WO2001034169 A1 WO 2001034169A1 DE 0003956 W DE0003956 W DE 0003956W WO 0134169 A1 WO0134169 A1 WO 0134169A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
angiogenesis
use according
plantago lanceolata
acteoside
Prior art date
Application number
PCT/DE2000/003956
Other languages
German (de)
English (en)
Inventor
Dietrich Paper
Original Assignee
Dietrich Paper
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dietrich Paper filed Critical Dietrich Paper
Priority to AU23489/01A priority Critical patent/AU2348901A/en
Publication of WO2001034169A1 publication Critical patent/WO2001034169A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates to a novel use of an extract from Plantago lanceolata or a fraction thereof or a lyophilisate thereof, or one or more active ingredients (in particular acteoside or isoacteoside) of the extract, or a Plantago lanceolata extract adjusted to phenylethanoids (e.g. acteoside or / and isoacteoside) to inhibit angiogenesis and inflammation-induced angiogenesis.
  • phenylethanoids e.g. acteoside or / and isoacteoside
  • the extracts are used for inflammation of the oral and pharynx mucosa, for the relief of irritation in catarrhs of the upper respiratory tract and for inflammatory changes in the skin.
  • the invention relates to the use of an extract from Plantago lanceolata, preferably the dry extract, the mother tincture, the fluid extract or a fraction thereof or a lyophilisate thereof, or one or more active ingredients of the extract for inhibiting angiogenesis and the angiogenesis caused by inflammation, especially for the treatment and prevention of tumor diseases, rheumatoid arthritis and other chronic inflammatory diseases, psoriasis, retinopathies and sinus infections of the teeth, but this is only an exemplary list and future therapeutic applications are also conceivable in other areas where the inhibition of angiogenesis plays a role plays.
  • the dosage of the fluid extract dry substance is between 20 mg and 2 g per day.
  • coated tablets, hard gelatin capsules, liquid preparations of the fluid extract dry substance are preferably used as dosage forms, topical use forms or injectables.
  • the new pharmacological effects have been demonstrated by the demonstrated inhibition of inflammation-induced angiogenesis on the chorion-allantoic membrane (CAM) of the incubated chicken egg by lyophilisates of the fluid extracts from Plantago lanceolata, as specified in more detail above.
  • CAM chorion-allantoic membrane
  • the HET-CAM test is part of a series of model tests to test the substances for their inhibition of inflammation-induced angiogenesis for possible therapeutic applications.
  • the advantage of the HET-CAM test is that it is one of the in vivo tests that allow a reliable statement about clinical relevance as an in vitro method. In this in vivo test, the complex system of angiogenesis with all of its functions and mediators is available, so that a comparatively reliable statement about the inhibitory effect of angiogenesis is possible.
  • the test is recognized as a screening method for the determination of substances with angiogenesis-inhibiting properties (Svahn, CM, M. Weber, C. Mattsson, K. Neiger, M. Palm carbohydr. Polym.
  • Angiogenesis is a physiologically differentiating tissue process in the development of the embryo, after the female period and during wound healing. This differentiation is based on capillaries, in which the basement membrane is partially dissolved, endothelial cells migrate and proliferate, merge into a tube and form a loop with neighboring proliferation sites. The basement membrane is formed on the newly created vessels. This process is controlled by antagonizing mediators.
  • the angiogenesis-stimulating factors include the Acidic Fibroblast Growth Factor (FGF-1), the Basic Fibroblast growth factor (FGF-2), the Vascular Endithelial growth Factor (VEGF), the Interleukin la (IL la) and other endogenous inhibitors against these stimulating factors and prevent angiogenesis in healthy people.
  • angiogenesis inhibitors still represent a therapeutic gap today, since no angiogenesis inhibitor approved for use in humans is yet available.
  • angiogenesis inhibitors e.g. Suramin, clinically proven, but therapeutic benefits are questioned due to toxic effects.
  • the plantago extracts described above and in particular the ingredient class of phenylethanoids show a new mode of action for their angiogenesis-inhibiting properties.
  • the plantago extracts and the phenylethanoids have strong antioxidant properties - as demonstrated in the DPPH test. Surprisingly, however, they have no pro-oxidative properties such as Vitamin C, which leads to the breakdown of glycosaminoglycans (e.g. heparin, chondroitin sulfates, heparan sulfates).
  • the plantago extracts and the phenylethanoids inhibited the breakdown of glycosaminoglycans, which is caused by free iron (II) ions and hydrogen peroxide.
  • glycosaminoglycans e.g. as part of the extracellular matrix, when split into small fragments that induce angiogenesis.
  • Active substances or extracts with such a mechanism of action are not yet known.
  • Tolerable mean daily doses of Herba Plantaginis lanceolata range up to 10g in phytotherapy, although no maximum dose can be seen yet. Possible dosages of the fluid extract dry substance are therefore preferably between 20 mg and 2 g.
  • Invention can be essential both individually and in any combination for realizing the invention in its various embodiments.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'un extrait de Plantago lanceolata ou d'une fraction de cette dernière ou d'un lyophilisat de cette dernière, ou bien d'un ou plusieurs constituants actifs de cet extrait, ou encore d'un extrait spécial de Plantago lanceolata, dosés pour correspondre à une teneur déterminée en principe actif, pour inhiber l'angiogénèse, en particulier l'angiogénèse provoquée par une infection.
PCT/DE2000/003956 1999-11-11 2000-11-10 Utilisation d'un extrait de plantago lanceolata WO2001034169A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU23489/01A AU2348901A (en) 1999-11-11 2000-11-10 Use of an extract from plantago lanceolata

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19954253.8 1999-11-11
DE19954253 1999-11-11

Publications (1)

Publication Number Publication Date
WO2001034169A1 true WO2001034169A1 (fr) 2001-05-17

Family

ID=7928673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2000/003956 WO2001034169A1 (fr) 1999-11-11 2000-11-10 Utilisation d'un extrait de plantago lanceolata

Country Status (2)

Country Link
AU (1) AU2348901A (fr)
WO (1) WO2001034169A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006114189A1 (fr) * 2005-04-28 2006-11-02 Indena S.P.A. Composition anti-rides
CN1319981C (zh) * 2002-07-19 2007-06-06 郭绪林 车前草总苷的制备工艺及其在医药中的应用
JP2007191416A (ja) * 2006-01-18 2007-08-02 Univ Kinki カンカニクジュヨウの抽出物より得られる強壮剤又は強精剤、配糖体化合物及びそれらの用途
CN102311466A (zh) * 2011-08-23 2012-01-11 北京科莱博医药开发有限责任公司 一种从车前子中提取苯乙醇苷类活性成分的方法
WO2016000663A1 (fr) * 2014-07-03 2016-01-07 杏辉天力（杭州）药业有限公司 Applications de l'extrait de cistanche tubulosa dans la préparation d'un médicament ou produit de protection les cellules de l'œil
CN106236762A (zh) * 2016-08-12 2016-12-21 成都中医药大学 松果菊苷和麦角甾苷的新用途
KR20190066779A (ko) * 2017-12-06 2019-06-14 김좌진 악테오사이드를 함유하는 뇌종양 치료 및 전이 억제용 약학 조성물
KR20190104118A (ko) * 2019-08-28 2019-09-06 김좌진 악테오사이드를 함유하는 뇌종양 치료 및 전이 억제용 약학 조성물
FR3093432A1 (fr) 2019-03-07 2020-09-11 Cep Composition cosmétique anti-âge

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07223964A (ja) * 1994-02-01 1995-08-22 Du Pont Merck Pharmaceut Co ホスホリパーゼａ２阻害剤
FR2733419A1 (fr) * 1995-04-27 1996-10-31 Blackborough Ltd Extraits vegetaux, leur procede de fabrication, conjugues phytoproteiques les contenant et leurs applications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07223964A (ja) * 1994-02-01 1995-08-22 Du Pont Merck Pharmaceut Co ホスホリパーゼａ２阻害剤
FR2733419A1 (fr) * 1995-04-27 1996-10-31 Blackborough Ltd Extraits vegetaux, leur procede de fabrication, conjugues phytoproteiques les contenant et leurs applications

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GAGLIARDI A ET AL: "INHIBITION OF ANGIOGENESIS BY SURAMIN", CANCER RESEARCH,US,AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 52, no. 18, 15 September 1992 (1992-09-15), pages 5073 - 5075, XP000602093, ISSN: 0008-5472 *
MARCHESAN, M. ET AL: "Investigation of the antiinflammatory activity of liquid extracts of Plantago lanceolata L.", PHYTOTHER. RES. (1998), 12(SUPPL. 1, SECOND INTERNATIONAL SYMPOSIUM ON NATURAL DRUGS, 1997), S33-S34, XP000984593 *
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 06 31 March 1999 (1999-03-31) *
PETTIT G R ET AL: "Antineoplastic agents, 107. Isolation of acteoside and isoacteoside from Castilleja linariaefolia.", JOURNAL OF NATURAL PRODUCTS, (1990). VOL. 53, NO. 2, PP. 456-8. JOURNAL CODE: JA4. ISSN: 0163-3864., Cancer Research Institute, Arizona State University, Tempe 85287., XP000984663 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1319981C (zh) * 2002-07-19 2007-06-06 郭绪林 车前草总苷的制备工艺及其在医药中的应用
WO2006114189A1 (fr) * 2005-04-28 2006-11-02 Indena S.P.A. Composition anti-rides
JP2007191416A (ja) * 2006-01-18 2007-08-02 Univ Kinki カンカニクジュヨウの抽出物より得られる強壮剤又は強精剤、配糖体化合物及びそれらの用途
CN102311466A (zh) * 2011-08-23 2012-01-11 北京科莱博医药开发有限责任公司 一种从车前子中提取苯乙醇苷类活性成分的方法
RU2688939C2 (ru) * 2014-07-03 2019-05-23 СИНЬФАР ТЯНЬ-ЛИ ФАРМАСЬЮТИКАЛ Ко., ЭлТэДэ. (ХАНЧЖОУ) Применение экстракта cistanche tubulosa в получении лекарственных средств или продуктов питания для защиты клеток глаза
WO2016000663A1 (fr) * 2014-07-03 2016-01-07 杏辉天力（杭州）药业有限公司 Applications de l'extrait de cistanche tubulosa dans la préparation d'un médicament ou produit de protection les cellules de l'œil
US10967029B2 (en) 2014-07-03 2021-04-06 Sinphar Pharmaceutical Co., Ltd. Method of using Cistanche tubulosa extract to prevent, slow down, or treat an eye disease caused by oxidative stress
CN106236762A (zh) * 2016-08-12 2016-12-21 成都中医药大学 松果菊苷和麦角甾苷的新用途
KR20190066779A (ko) * 2017-12-06 2019-06-14 김좌진 악테오사이드를 함유하는 뇌종양 치료 및 전이 억제용 약학 조성물
KR102018085B1 (ko) 2017-12-06 2019-09-04 김좌진 악테오사이드를 함유하는 뇌종양 치료 및 전이 억제용 약학 조성물
FR3093432A1 (fr) 2019-03-07 2020-09-11 Cep Composition cosmétique anti-âge
KR20190104118A (ko) * 2019-08-28 2019-09-06 김좌진 악테오사이드를 함유하는 뇌종양 치료 및 전이 억제용 약학 조성물
KR102135148B1 (ko) 2019-08-28 2020-07-20 김좌진 악테오사이드를 함유하는 뇌종양 치료 및 전이 억제용 약학 조성물

Also Published As

Publication number Publication date
AU2348901A (en) 2001-06-06

Similar Documents

Publication Publication Date Title
AT393793B (de) Verfahren zur herstellung eines pharmazeutischen praeparates mit gefaesschuetzender wirkung
EP1064009B2 (fr) Utilisation d'extraits de plants d'iris, de cimicifuga racemosa et de tectorigenine comme medicament oestrogenoide organoselectif sans effet uterotrope
DE60027481T2 (de) Zusammensetzung zur Behandlung von chronischer venöser Insuffizienz mit einem Extrakt aus Blättern von roten Weinreben
DE69825279T2 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
WO2001034169A1 (fr) Utilisation d'un extrait de plantago lanceolata
WO2003080085A1 (fr) Extraits de plantes et leur utilisation
EP0869807B1 (fr) Emploi d'un medicament et utilisation d'un melange de substances pour la production d'un medicament
EP0975350B1 (fr) Utilisation d'un extrait d'alchemilla vulgaris
EP1682162B1 (fr) Utilisation de figue de barbarie (opuntia) pour la préparation d'un médicament pour le traitment des depressions
DE10047835A1 (de) Verwendung eines Extraktes von Lippia citriodora
DE2912438C2 (fr)
EP1117417B1 (fr) Preparation vegetale d'action pharmaceutique destinee au traitement de la migraine
DE10359384A1 (de) Verwendung eines Extraktes von Aloysia triphylla als Matrixprotektor
DE69918852T2 (de) Zusammensetzung enthaltend eine mischung von bioflavonoiden
DE3827953C2 (fr)
EP0256353A2 (fr) Traitement pharmaceutique contre une mauvaise absorption d'aliments ou de médicaments oraux
DE69919040T2 (de) Verwendung einer synergistischen zusammensetzung zur herstellung eines medikaments zur behandlung von lebererkrankungen
EP1427430A2 (fr) Utilisation d'extraits de l'espece cimicifuga en tant que medicaments organoselectifs pour traiter des maladies de l'appareil genito-urinaire causees par des hormones sexuelles
DE2720420A1 (de) Wirkstoffkombination gegen sonnenerythem und diese enthaltendes arzneimittel
CH677878A5 (fr)
EP0002803B1 (fr) Cis triméthyl-3,3,5 cyclohexanol utilisable dans le traitement des maladies bilieuses
DE60020888T2 (de) Zusatz aus kräutern zur behandlung von kognitiven störungen aufgrund von östrogenverlust
EP0241498B1 (fr) Medicament analgesique et anti-inflammatoire a base de plantes
DE60129748T2 (de) Biologisch wirksame chloroform fraktion eines extraktes erhalten aus der mangrovenpflanze salvadora persica l
DE3844798C2 (en) Medicaments contg. Urtica kiovensis extract

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase